Global CROs Help BioPharma Reach China and APAC Patients and Speed Clinical Trials

Author: Dan Gallagher, Emerald Clinical Trials SVP, Business Development.

Dan Gallagher is a senior commercial leader on Emerald Clinical Executive Team with 17 years of drug development experience driving business development, operational transformation, and strategic growth for global CROs and biotech service providers. Currently serving as Senior Vice President, Head of Business Development and acting Chief Commercial Leader at Emerald Clinical, Dan leads a global commercial organization spanning business development, contracts & proposals, and marketing.

In the past year, China has rapidly emerged as a key strategic consideration for sponsors planning to run global studies. That marks a sharp shift from the traditional biotech and pharma regional focus, where APAC was often treated as secondary to the US and Europe and brought into development plans only later if timelines, funding, or commercial priorities allowed. That approach is changing rapidly. Across the industry, sponsors are recognizing that APAC is no longer simply an optional expansion geography.

China and the APAC region in general are increasingly becoming one of the most important operational and strategic imperatives for accelerating clinical development timelines, accessing patients faster, and unlocking therapeutic asset value earlier. In short, APAC is becoming the next innovation hub for drug development. The shift is already under way and some sponsors have adapted to it much more quickly than others. Part of the reason is simple competitive pressure. Sponsors are competing for the same investigators, the same sites, and often the same patient populations across existing geographies in the US and Europe.

To read the full article please fill out the form below.